Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 414

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

Open access
Moore, Kathleen N., Bookman, Michael, Sehouli, Jalid, Miller, Austin, Anderson, Charles, Scambia, Giovanni, Myers, Tashanna, Taskiran, Cagatay, Robison, Katina, Mäenpää, Johanna, Willmott, Lyndsay, Colombo, Nicoletta, Thomes-Pepin, Jessica, Liontos, Michalis, Gold, Michael A., Garcia, Yolanda, Sharma, Sudarshan K., Darus, Christopher J., Aghajanian, Carol, Okamoto, Aikou, Wu, Xiaohua, Safin, Rustem, Wu, Fan, Molinero, Luciana, Maiya, Vidya, Khor, Victor K., Lin, Yvonne G., Pignata, Sandro·2021·Journal of Clinical Oncology

Abstract

PURPOSE: To evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC). METHODS: This multicenter placebo-controlled double-blind randomized phase III trial (ClinicalTrials.gov identifier: NCT03038100 ) enrolled patients with newly diagnosed untreated International Federation of Gynecology and Obstetrics (FIGO) stage III or IV OC who either had undergone primary cytoreductive surgery with macroscopic residual disease or were planned to receive neoadjuvant chemotherapy and interval surgery. Patients were stratified by FIGO stage, Eastern Cooperative Oncology Group performance status, tumor immune cell PD-L1 staining, and treatment strategy and randomly assigned 1:1 to receive 3-weekly cycles of atezolizumab 1,200 mg or placebo (day 1, cycles 1-22), with paclitaxel plus carboplatin (day 1, cycles 1-6) plus bevacizumab 15 mg/kg (day 1, cycles 2-22), omitting perioperative bevacizumab in neoadjuvant patients. The co-primary end points were investigator-assessed progression-free survival and overall survival in the intention-to-treat and PD-L1–positive populations. RESULTS: Between March 8, 2017, and March 26, 2019, 1,301 patients were enrolled. The median progression-free survival was 19.5 versus 18.4 months with atezolizumab versus placebo, respectively (hazard ratio, 0.92; 95% CI, 0.79 to 1.07; stratified log-rank P = .28), in the intention-to-treat population and 20.8 versus 18.5 months, respectively (hazard ratio, 0.80; 95% CI, 0.65 to 0.99; P = .038), in the PD-L1–positive population. The interim (immature) overall survival results showed no significant benefit from atezolizumab. The most common grade 3 or 4 adverse events were neutropenia (21% with atezolizumab v 21% with placebo), hypertension (18% v 20%, respectively), and anemia (12% v 12%). CONCLUSION: Current evidence does not support the use of immune checkpoint inhibitors in newly diagnosed OC. Insight from this trial should inform further evaluation of immunotherapy in OC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.21.00306

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 414

Metadata

Authors
Moore, K. N., Bookman, M., Sehouli, J., Miller, A., Anderson, C., Scambia, G., Myers, T., Taskiran, C., Robison, K., Mäenpää, J., Willmott, L., Colombo, N., Thomes-Pepin, J., Liontos, M., Gold, M. A., Garcia, Y., Sharma, S. K., Darus, C. J., Aghajanian, C., Okamoto, A., Wu, X., Safin, R., Wu, F., Molinero, L., Maiya, V., Khor, V. K., Lin, Y. G., & Pignata, S.
Venue
Journal of Clinical Oncology
Published
2021-06-10
Volume
39
Issue
17
Pages
1842-1855
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3153473864
Cited by
414
References
15
FWCI
47.01
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). https://app.cochat.ai/papers/10.1200/jco.21.00306
The paper
Moore, K. N., Bookman, M., Sehouli, J., Miller, A., Anderson, C., Scambia, G., Myers, T., Taskiran, C., Robison, K., Mäenpää, J., Willmott, L., Colombo, N., Thomes-Pepin, J., Liontos, M., Gold, M. A., Garcia, Y., Sharma, S. K., Darus, C. J., Aghajanian, C., . . . Pignata, S. (2021). Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). Journal of Clinical Oncology. https://doi.org/10.1200/jco.21.00306

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.